PP
PVLA

Paloma Partners’s Palvella Therapeutics PVLA Stock Holding History

Paloma Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-161
Closed -$49K – 2317
2021
Q4 		$49K Buy
+161
New +$51.6K ﹤0.01% 1832
2019
Q3 		– Sell
-244
Closed -$92K – 2342
2019
Q2 		$92K Buy
+244
New +$72.8K ﹤0.01% 1635

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Paloma Partners's PVLA Position: Q1 2022 in Review

Paloma Partners sold out of Palvella Therapeutics (PVLA) in Q1 2022, closing a stake of 161 shares — an estimated $49K sold.

Paloma Partners first reported a position in PVLA in Q2 2019 and held it in 2 quarters. The position peaked at $92K in Q2 2019. 71 funds tracked by Wall St. Rank hold PVLA as of Q1 2022.

  • Paloma Partners reported no remaining Palvella Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Paloma Partners sold 161 Palvella Therapeutics shares in Q1 2022, an estimated $49K.
  • Paloma Partners first reported a position in Palvella Therapeutics in Q2 2019 and held it in 2 quarters.
  • Paloma Partners's Palvella Therapeutics position peaked at $92K in Q2 2019.
  • 71 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2022.

Based on Paloma Partners's 13F filing for Q1 2022, filed 16 May 2022.